Media.Player

Structure Based Design of Anti-Parkinson's Disease Compounds Targeting Synuclein Oligomerization

Detailed Technology Description

Recent work by UC San Diego investigators have focused on a specific region of alpha-synuclein critical to the aggregation process. Through the use of structure based design, peptidomimetic and peptide compounds were designed that block alpha-synuclein aggregation and neurodegeneration in an in-vitro model system. The initial compounds or their derivatives may serve as lead compounds or core structures that mimic natural chaperones that inhibit aggregation. This approach represents a radical shift from current approaches where reactive dyes are used in conjunction with the aggregated proteins to screen large chemical libraries, which may contain reactive compounds but potentially lack the required high degree of specificity to be a viable therapeutic candidate.

Application No.

8450481

Others

Related Materials

Dynamics of alpha-synuclein Aggregation and Inhibition of Pore-like Oligomer Development by beta-synuclein. Masliah, et. al. The FEBS Journal 274 (2007) 1862-1877

Additional Technologies by these Inventors

• System for Tracking Sharps and Tools in the Operating Room
• Peptides Targeted to the CNS for Clearance of Protein Aggregates in Alzheimer's Disease

Tech ID/UC Case

19415/2007-274-0

Related Cases

2007-274-0

*Abstract

Researchers at UC San Diego's School of Medicine have invented a nanostructured device with a significantly improved ZT figure of merit.

The pathogenesis of many neurodegenerative diseases (i.e., Parkinson’s disease and Lewy body dementia) is believed to involve the accumulation of alpha-synuclein, although how this buildup results in neuronal degeneration is still unclear. It has been shown that under pathological conditions, alpha-synuclein can aggregate into pentamers and hexamers that form pore-like structures. A better understanding of these oligomerization dynamics and subsequent fibril formation may lead to new avenues of treatment for Parkinson’s disease or other neurodegenerative diseases characterized by this type of aggregation phenomenon.

*IP Issue Date

May 28, 2013

*Principal Investigator

Name: Eliezer Masliah

Department:

Name: Edward Rockenstein

Department:

Name: Igor Tsigelny

Department:

Name: Wolfgang Wrasidlo

Department:

Country/Region

USA